Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 1
2005 2
2006 3
2007 4
2008 3
2009 11
2010 8
2011 16
2012 7
2013 11
2014 13
2015 9
2016 6
2017 9
2018 8
2019 4
2020 12
2021 9
2022 22
2023 13
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

167 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean yin chang mi[Author] (2 results)?
A global study for acute myeloid leukemia with RARG rearrangement.
Zhu HH, Qin YZ, Zhang ZL, Liu YJ, Wen LJ, You MJ, Zhang C, Such E, Luo H, Yuan HJ, Zhou HS, Liu HX, Xu R, Li J, Li JH, Hao JP, Jin J, Yu L, Zhang JY, Liu LP, Zhang LP, Huang RB, Shen SH, Gao SJ, Wang W, Yan XJ, Zhang XY, Du X, Chu XX, Yu YF, Wang Y, Mi YC, Lu Y, Cai Z, Su Z, Taussig DC, MacMahon S, Ball ED, Wang HY, Welch JS, Yin CC, Borthakur G, Sanz MA, Kantarjian HM, Huang JY, Hu J, Chen SN. Zhu HH, et al. Blood Adv. 2023 Jul 11;7(13):2972-2982. doi: 10.1182/bloodadvances.2022008364. Blood Adv. 2023. PMID: 36799929 Free PMC article.
Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia.
Zhang Q, Riley-Gillis B, Han L, Jia Y, Lodi A, Zhang H, Ganesan S, Pan R, Konoplev SN, Sweeney SR, Ryan JA, Jitkova Y, Dunner K Jr, Grosskurth SE, Vijay P, Ghosh S, Lu C, Ma W, Kurtz S, Ruvolo VR, Ma H, Weng CC, Ramage CL, Baran N, Shi C, Cai T, Davis RE, Battula VL, Mi Y, Wang J, DiNardo CD, Andreeff M, Tyner JW, Schimmer A, Letai A, Padua RA, Bueso-Ramos CE, Tiziani S, Leverson J, Popovic R, Konopleva M. Zhang Q, et al. Among authors: mi y. Signal Transduct Target Ther. 2022 Feb 21;7(1):51. doi: 10.1038/s41392-021-00870-3. Signal Transduct Target Ther. 2022. PMID: 35185150 Free PMC article.
Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia.
Gu R, Liu F, Zou D, Xu Y, Lu Y, Liu B, Liu W, Chen X, Liu K, Guo Y, Gong X, Lv R, Chen X, Zhou C, Zhong M, Wang H, Wei H, Mi Y, Qiu L, Lv L, Wang M, Wang Y, Zhu X, Wang J. Gu R, et al. Among authors: mi y. J Hematol Oncol. 2020 Sep 7;13(1):122. doi: 10.1186/s13045-020-00953-8. J Hematol Oncol. 2020. PMID: 32894185 Free PMC article. Clinical Trial.
Assessment of mortality-related risk factors and effective antimicrobial regimens for treatment of bloodstream infections caused by carbapenem-resistant Pseudomonas aeruginosa in patients with hematological diseases.
Zhen S, Zhao Y, Chen Z, Zhang T, Wang J, Jiang E, Zhang F, Mi Y, Zhu X, Han M, Xiao Z, Wang J, Feng S. Zhen S, et al. Among authors: mi y. Front Cell Infect Microbiol. 2023 Jun 21;13:1156651. doi: 10.3389/fcimb.2023.1156651. eCollection 2023. Front Cell Infect Microbiol. 2023. PMID: 37415825 Free PMC article.
167 results